Form 4: Mirum CFO Reports Future RSU Vesting and Tax-Related Share Sale

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, reported pre-scheduled transactions for September 2025, including RSU vesting and a subsequent share sale for tax obligations.

Summary

• Mirum Pharmaceuticals, Inc. CFO, Eric Bjerkholt, filed a Form 4 reporting future transactions under a Rule 10b5-1 plan.
• On September 11, 2025, Mr. Bjerkholt is scheduled to acquire 18,333 shares of common stock due to the vesting of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of common stock.
• On September 12, 2025, Mr. Bjerkholt is scheduled to sell 9,578 shares of common stock at a price of $76.01 per share.
• The sale is designated to cover tax withholding obligations associated with the RSU vesting.
• Following these transactions, Mr. Bjerkholt's direct beneficial ownership will be 39,945 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to executive compensation, pre-scheduled under a Rule 10b5-1 plan. The vesting of RSUs is generally positive as it indicates executive retention and alignment, while the subsequent sale for tax purposes is a neutral, expected event. No significant positive or negative operational news is conveyed, leading to a slightly positive to neutral sentiment.

Positives

• The vesting of restricted stock units indicates the achievement of performance or time-based milestones, aligning management's interests with shareholders.
• The transactions are pre-scheduled under a Rule 10b5-1 plan, demonstrating a structured approach to insider trading and reducing concerns about opportunistic selling.
• The sale of shares is explicitly for tax withholding, which is a common and expected practice for RSU vesting and not typically a negative signal.

Negatives

• A reduction in the CFO's direct beneficial ownership, even if for tax purposes, slightly decreases their direct equity stake in the company.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on pre-scheduled insider equity transactions.

Industry Context

This is an insider transaction report, which is specific to the company and its executive compensation structure. It does not directly provide broader industry trends or competitive analysis. The reported transactions are routine for executives receiving equity compensation in the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• The sale of shares to cover tax withholding upon RSU vesting is a very common and standard practice for executives across all industries, including the pharmaceutical sector, who receive equity compensation.
• The use of a Rule 10b5-1 plan for these transactions aligns with best practices for insider trading, providing a pre-arranged schedule to avoid accusations of trading on material non-public information.

Related Party Transactions

• The reported transactions involve the company's Chief Financial Officer, Eric Bjerkholt, and the company's common stock, which constitutes a related party transaction under Section 16 reporting requirements.

Stakeholder Impact

• Shareholders: The transactions represent a minor, pre-scheduled change in the CFO's direct ownership. The sale for tax purposes is a common occurrence and generally not seen as a negative signal, especially when conducted under a 10b5-1 plan.
• Employees: The RSU vesting demonstrates the company's executive compensation structure and retention mechanisms, which can be a positive for employee morale and alignment.

Next Steps

• The remaining installments of the restricted stock units are expected to vest in successive equal annual installments, with the next one likely on September 11, 2026.

Key Dates

Recommendation

The Form 4 filing details pre-scheduled insider transactions under a Rule 10b5-1 plan, where the CFO will acquire shares through RSU vesting and subsequently sell a portion to cover tax obligations. This is a routine and expected event, not indicative of new fundamental information about the company's operational performance, strategic direction, or financial health. Therefore, a 'hold' recommendation is appropriate as there's no new information to justify a 'buy' or 'sell' decision based solely on this filing.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Transaction, CFO, Eric Bjerkholt, Restricted Stock Units, RSU Vesting, Share Sale, Tax Withholding, Rule 10b5-1 Plan